Clinical trial • Phase I • Oncology
MST-0312 for Solid malignancies
Phase I trial of MST-0312 for Solid malignancies. open-label. 42 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Solid malignancies
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 02-02-2026
- First CTIS Authorization Date
- 13-03-2026
Trial design
open-label Phase I trial across 7 sites in Spain.
- Open Label
- Yes
- Target Sample Size
- 42
Eligibility
Recruits 42 Vulnerable populations not selected; no details on consent or assent provided..
- Vulnerable Population
- Vulnerable populations not selected; no details on consent or assent provided.
Recruitment
- Planned Sample Size
- 42
- Recruitment Window Months
- 44
Geography
- Total Number Of Sites
- 7
- Total Number Of Participants
- 42
Spain
- Earliest CTIS Part Ii Submission Date
- 24-02-2026
- Latest Decision Or Authorization Date
- 13-03-2026
- Processing Time Days
- 17
- Number Of Sites
- 7
- Number Of Participants
- 42
Sites
- Site Name
- Hospital Quironsalud Barcelona
- Department Name
- Instituto de Oncología de Barcelona
- Contact Person Name
- Omar Saavedra
- Contact Person Email
- osaavedra@nextoncology.eu
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Oncología Médica
- Contact Person Name
- Javier Torres Jiménez
- Contact Person Email
- Javier.torres@salud.madrid.org
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncología
- Contact Person Name
- Victor Moreno
- Contact Person Email
- victor.moreno@startmadrid.com
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Centro Integral Oncológico Clara Campall (CIOCC) Phase I trials unit
- Contact Person Name
- Emiliano Calvo Aller
- Contact Person Email
- emiliano.calvo@startmadrid.com
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Inmunología médica & inmunoterapía
- Contact Person Name
- Ignacio Melero
- Contact Person Email
- imelero@unav.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncología Médica
- Contact Person Name
- Elena Garralda
- Contact Person Email
- egerralda@vhio.net
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Oncología Médica
- Contact Person Name
- Desamparados Roda
- Contact Person Email
- droda@incliva.es
Sponsor
Primary sponsor
- Full Name
- Mestag Therapeutics Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- MST-0312
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)